State of Wyoming Purchases 2,968 Shares of DaVita Inc. $DVA

State of Wyoming acquired a new stake in shares of DaVita Inc. (NYSE:DVA) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,968 shares of the company’s stock, valued at approximately $519,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. CoreCap Advisors LLC grew its stake in shares of DaVita by 161.7% in the 3rd quarter. CoreCap Advisors LLC now owns 157 shares of the company’s stock valued at $27,000 after buying an additional 97 shares during the period. Root Financial Partners LLC raised its stake in DaVita by 128.0% during the 1st quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock worth $29,000 after buying an additional 105 shares during the period. Compass Financial Management LLC acquired a new position in DaVita during the 2nd quarter worth approximately $72,000. NewEdge Advisors LLC boosted its holdings in DaVita by 66.4% in the second quarter. NewEdge Advisors LLC now owns 361 shares of the company’s stock worth $80,000 after acquiring an additional 144 shares in the last quarter. Finally, Western Wealth Management LLC bought a new position in DaVita in the first quarter worth approximately $60,000. Institutional investors own 90.12% of the company’s stock.

DaVita Price Performance

NYSE:DVA opened at $185.37 on Tuesday. DaVita Inc. has a one year low of $101.00 and a one year high of $247.49. The company has a market cap of $11.83 billion, a PE ratio of 13.65, a PEG ratio of 0.48 and a beta of 0.80. The firm has a 50-day moving average of $181.58 and a 200-day moving average of $176.90.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Thursday, October 29th. The company reported $3.82 earnings per share for the quarter, beating the consensus estimate of $3.57 by $0.25. The business had revenue of $3.58 billion for the quarter, compared to analysts’ expectations of $3.52 billion. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The firm’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same quarter last year, the firm earned $2.51 EPS. On average, equities research analysts expect that DaVita Inc. will post 14.74 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on DVA. Weiss Ratings raised DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, October 9th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $265.00 target price on shares of DaVita in a research report on Wednesday, August 5th. Wall Street Zen cut DaVita from a “buy” rating to a “hold” rating in a report on Saturday. Raymond James Financial set a $220.00 price target on shares of DaVita in a research report on Friday, August 7th. Finally, Zacks Research downgraded shares of DaVita from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Four analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, DaVita presently has an average rating of “Moderate Buy” and a consensus target price of $235.86.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a health care services company focused on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with chronic kidney failure, including in-center hemodialysis, home dialysis and related clinical support services.

DaVita also offers integrated kidney care programs intended to support patients across the stages of chronic kidney disease. Its services may include care coordination, disease management, education, transplant support and other services designed to improve clinical outcomes and help manage the needs of patients with complex kidney conditions.

The company operates a network of dialysis centers and related facilities in the United States and serves patients in select international markets.